SRSF2 is mutated in 50% of patients with CMML, 10–14% of patients with AML, and 20–30% of patients with MDS (Yoshida et al., 2011), where these mutations confer an increased risk of transformation from MDS to AML (Papaemmanuil et al., 2013). This evidence concerns the gene SRSF2 and myelodysplastic syndrome.